You can’t patent a piece of the human genome, the Supreme Court declared in a unanimous decision in June. So why, in the weeks after, did Myriad Genetics — the company whose patents were voided — sue a competitor for patent infringement for testing for the very gene declared unpatentable by the Court?
Some background: In the case, the Association for Molecular Pathology brought suit against Myriad because it thought it one company shouldn’t have the sole rights to a segment of the human genome — especially when that segment indicates a person’s breast-cancer risk. The organization argued that Myriad’s monopoly of testing for the malignant variants of the BRCA1 and BRCA2 genes plugged up innovation in the science and drove up costs for patients. Those with a certain variant of these genes have a 60 percent likelihood of developing breast cancer. If you recall, the actress Angelina Jolie discovered she was a carrier for the gene, which prompted her to undergo a double mastectomy to void the risk.
The Supreme Court largely agreed with the Association for Molecular Pathology, declaring slices of the naturally occurring human genome unfit for patents. And right after the decision, two companies — Ambry Genetics and Gene By Gene — saw an opening to start offering the breast-cancer screening tests that Myriad had been performing. And then Myriad sued … for patent infringement.
The short answer to how Myriad could justify its move is this: Science is so very complicated, and the Court ruled narrowly.
In its decision, the Supreme Court maintained that man-made copies of human DNA were still patentable. These pieces are called cDNA, which are slightly altered copies of the naturally occurring genes. They are useful tools for genetic testing, since they can be used to relay a person’s genetic information in a stable form. This bit of the ruling, in effect, allows Myriad to still lay claim to much of the breast-cancer testing.
Writing in Scientific American, Megan Krench, a geneticist, provides a more detailed answer (Reader’s Digest version: While the Court took away Myriad’s castle, they left them the moat):
Why do Myriad’s patent rights to cDNA matter? There are several reasons. First, cDNA is an important research tool. For example, the edited cDNA sequence, not the longer DNA sequence, is often used to create animal models of diseases. Those models are essential for researching new treatments and cures. Without the licensing to BRCA1/2 cDNA, certain cancer research may be restricted to Myriad. Next, cDNA is critical for developing new diagnostic tests for genetic disorders. Since the BRCA1/2 genes themselves are not patented, it may be possible for other companies to develop new genetic tests — but the patented cDNA will make this process much more difficult.
In all, after the Court’s decision, Myriad argues in the documents filed against Ambry, it has retained 515 of 520 patent claims regarding the test.
This issue is going to get another go-around in the courts, as Ambry has countersued, citing antitrust violations. A lot of money is at stake here for Myriad and its competitors. According to Ars Technica, Myriad hauled in $57 million from the tests that can cost $3,000 or more. And the introduction of competitors, however brief, pushed the market price way down: Ambry started to sell the tests for $2,280; Gene by Gene offered a relative steal at $995. The genetic-testing industry is on the verge of booming, as I reported in June. By 2021, the national costs for genetic testing could rise to $25 billion. Right now, they are around $5 billion.
What We're Following See More »
"Even if House Republicans manage to get enough members of their party on board with the latest version of their health care bill, they will face another battle in the Senate: whether the bill complies with the chamber’s arcane ... Byrd rule, which stipulates all provisions in a reconciliation bill must affect federal spending and revenues in a way that is not merely incidental." Democrats should have the advantage in that fight, "unless the Senate pulls another 'nuclear option.'”
The House has passed a one-week spending bill that will avert a government shutdown which was set to begin at midnight. Lawmakers now have an extra week to come to a longer agreement which is expected to fund the government through the end of the fiscal year in September. The legislation now goes to the Senate, where it is expected to pass before President Trump signs it.
President Trump’s portrayal of an effort to funnel more Medicaid dollars to Puerto Rico as a "bailout" is complicating negotiations over a continuing resolution on the budget. "House Democrats are now requiring such assistance as a condition for supporting the continuing resolution," a position that the GOP leadership is amenable to. "But Mr. Trump’s apparent skepticism aligns him with conservative House Republicans inclined to view its request as a bailout, leaving the deal a narrow path to passage in Congress."
Democrats in the House are threatening to shut down the government if Republicans expedite a vote on a bill to repeal and replace Obamacare, said Democratic House Whip Steny Hoyer Thursday. Lawmakers have introduced a one-week spending bill to give themselves an extra week to reach a long-term funding deal, which seemed poised to pass easily. However, the White House is pressuring House Republicans to take a vote on their Obamacare replacement Friday to give Trump a legislative victory, though it is still not clear that they have the necessary votes to pass the health care bill. This could go down to the wire.